Floatz logo

BAY94-8393

Bone Neoplasms

BayerDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Bone Neoplasms cohort.

Asset / SponsorPhaseRating
Zoledronate
AstraZeneca
Phase 4BB
Irinotecan
Actuate Therapeutics Inc.
Phase 3BB
Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4BB
azd0530
AstraZeneca
Phase 2B
GEMOGENOVATUCEL-T
Gradalis, Inc.
Phase 3B

View all 16 →

Same molecule, other indications

BAY94-8393 is also rated in:

prostate neoplasmDormant
D
Indicative ·
30 / 100
View asset →
lytic metastatic bone lesionDormant
D
Indicative ·
30 / 100
View asset →
breast neoplasmDormant
D
Indicative ·
28 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →